Structural analog of naltrexone, q.v., with opiate antagonist activity. Prepn: J. Fishman, US 3814768 (1974 to M. J. Lewenstein); E. F. Hahn et al., J. Med. Chem. 18, 259 (1975). Improved synthesis: P. C. Meltzer, J. W. Coe, EP 140367; eidem, US 4535157 (both 1985 to Key Pharm.). Comparative evaluation of efficacy in mice: R. D. Heilman et al., Res. Commun. Chem. Pathol. Pharmacol. 13, 635 (1976). HPLC determn in human plasma: J. Hsiao, R. Dixon, ibid. 42, 449 (1983). Receptor binding activity in rat brain: M. E. Michel et al., Methods Find. Exp. Clin. Pharmacol. 7, 175 (1985). Clinical evaluation of narcotic antagonism: T. J. Gal, C. A. DiFazio, Anesthesiology 64, 175 (1986). Pharmacokinetics in humans: R. Dixon et al., Clin. Pharmacol. Ther. 39, 49 (1986); eidem, J. Clin. Pharmacol. 27, 233 (1987). Use as antagonist to opioid-induced immobilization in large animals: T. J. Kreeger et al., J. Wildl. Dis. 23, 619 (1987). Comprehensive description: H. G. Brittain, Anal. Profiles Drug Subs. Excip. 24, 351-395 (1996).
Narcotic antagonist.
Narcotic Antagonist